Physician profile
Bijoy Sam
NPI 1689410599
$2,016.63
in general payments reported to CMS, 2019-2025
11 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $848 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $351.28 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $314.58 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $278.68 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $259.30 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $232.50 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $214.72 | 2024-2025 | Invega Sustenna |
| Lundbeck LLC | $175.55 | 2024-2025 | Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $122.92 | 2024 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.93 | 2024 | |
| Abbvie INC. | $21.92 | 2024 | |
| Lilly USA, LLC | $21.25 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijoy Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.